Interventional Neurorehabilitation for Promoting Functional Recovery Post-Craniotomy: A Proof-of-Concept

Anujan Poologaindran[1,2] MSc, Christos Profyris[3,4] FC Neurosurg (SA), Isabella M. Young[4] BSc, Nicholas B. Dadario BSc[4,5], Syed A. Ahsan[4] BMed, Kassem Chendeb[4] CS, Robert G. Briggs[6] MD, Charles Teo[4] FRACS, Rafael Romero-Garcia[1] PhD, John Suckling[1,2] PhD, *Michael E. Sughrue[1,4] MD

[1]Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK
[2]The Alan Turing Institute, British Library, London, UK
[3]Netcare Linksfield Hospital, Johannesburg, South Africa
[4]Department of Neurosurgery, Prince of Wales Private Hospital, Sydney, Australia
[5]Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
[6]Department of Neurosurgery, University of Southern California, Los Angeles, California, USA
*Corresponding Author, sughruevs@gmail.com

Corresponding Author: Dr.Michael E. Sughrue

Neurosurgeon, Dept. of Neurosurgery, Prince of Wales Private Hospital, Sydney, Australia

Visiting Researcher, Department of Psychiatry, University of Cambridge, Cambridge, UK

sughruevs@gmail.com

P-(02) 8328 0975 / F-(02) 9169 6375

Running Title: Interventional Neurorehabilitation

Interventional Neurorehabilitation for Promoting Functional Recovery Post-Craniotomy: A Proof-of-Concept

ABSTRACT

Purpose: The human brain is a highly plastic 'complex' network –it is highly resilient to damage and capable of self-reorganisation after a large perturbation. Clinically, neurological deficits secondary to iatrogenic injury have very few active treatments. New imaging and stimulation technologies, though, offer promising therapeutic avenues to accelerate post-operative recovery trajectories. In this study, we sought to establish the safety profile for 'interventional neurorehabilitation': connectome-based therapeutic brain stimulation to drive cortical reorganisation and promote functional recovery post-craniotomy.

Methods: In n=34 glioma patients who experienced post-operative motor or language deficits, we used connectomics to construct single-subject cortical networks. Based on their clinical and connectivity deficit, patients underwent network-specific Transcranial Magnetic Stimulation (TMS) sessions daily over five consecutive days. Patients were then assessed for TMS-related side effects and improvements.

Results: 31/34 (91%) patients were successfully recruited and enrolled for TMS treatment within two weeks of glioma surgery. No seizures or serious complications occurred during TMS rehabilitation and one-week post-stimulation. Transient headaches were reported in 4/31 patients but improved after a single session. No neurological worsening was observed while a benefit was noted in 28/31 patients post-TMS. We present two clinical vignettes and a video demonstration of interventional neurorehabilitation.

Conclusions: For the first time, we demonstrate the safety profile and ability to recruit, enrol, and complete TMS acutely post-craniotomy in a high seizure risk population. Given the lack of randomisation and controls in this study, prospective randomised sham-controlled stimulation trials are now warranted to establish the efficacy of interventional neurorehabilitation following craniotomy.

Interventional Neurorehabilitation for Promoting Functional Recovery Post-Craniotomy: A Proof-of-Concept

Introduction

The human brain is a highly plastic 'complex' network [1,2]: it self-organises without a hard blueprint, it adapts to evolving circumstances, and can withstand external insults. Our thoughts and behaviour are directly governed by how our brain networks handle, orchestrate, and execute various internal and external demands [3]. Nevertheless, similar to other naturally-occurring networks, brain networks can only endure a finite amount of damage before becoming maladaptive and fragmented [4].

The practice of neurosurgery is based on therapeutically altering the brain's global workspace to improve clinical outcomes [5,6]. However, since the antiquity of neurosurgery, few strategies have been employed to directly address neurological deficits due to iatrogenic injury. In fact, the usual approach is to send patients to physiotherapy and hope they improve over time in a sufficiently stimulating environment. Moreover, rehabilitation is further complicated when surgical pathology implicates critical areas for motor initiation, alertness, motivation, and consciousness [7]. Furthermore, advanced neurocomputational models suggest the capacity for neuroplasticity greatly varies based on the type of cortical damage which has occurred [8]. Ideally, a fundamental goal of neuro-oncological surgery should be to drive cortical reorganisation and promote functional recovery in the immediate post-operative period. To advance this viewpoint, we coin a new concept called 'interventional neurorehabilitation': connectome-based therapeutic brain stimulation to promote network plasticity and functional recovery.

Over the past few years, monumental advancements have been made in neuroimaging and neurostimulation technologies. Today, state-of-the art connectome methods enable neuroscientists to make highly accurate single-subject predictions on cognition [9-11]. In addition, we are beginning to non-invasively stimulate focally at-depth without perturbing overlaying cortical structures [12]. However, before leveraging the most advanced technologies for interventional neurorehabilitation, applying well-studied existing stimulation approaches is

sensible. Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved stimulation

therapy routinely performed at hospitals across the world [13]. Given its relative ease and non-

invasiveness, the field of TMS has flourished to treat a range of neurological and psychiatric

illnesses. In acute and chronic stroke patients, rTMS facilitates cortical reorganization leading to

functional preservation or compensation in motor and language abilities [14]. Unfortunately,

prognosis is still poor in many these patients, which may be explained by the limited capacity for

effective cerebral plasticity following some acute injuries compared to slow growing tumors [8].

While meta-analyses highlight the remarkable safety of rTMS in ischemic stroke patients with

extremely low-risks for seizures [15,16], there remains limited descriptions on the safety and

efficacy of this treatment modality in tumor patients in the acute post-operative period. Given the

striking advances in fields outside neuro-oncology, individualised TMS therapy merits

investigation to accelerate recovery trajectories post-craniotomy.

In this proof-of-concept study, we sought to establish the safety profile and ability to

recruit, enrol, and complete connectome-guided TMS to enhance network plasticity and promote

functional recovery following glioma surgery.

Methods

49 This study was approved by the Human Research Ethics Committee of the South Eastern Sydney

50 Local Health District (SESLHD). Patients provided written informed consent prior to enrolling

51 in our study. All methods were performed in accordance with relevant guidelines and regulations

52 Declaration of Helsinki. The clinical trial was registered at clinicaltrials.gov (NCT03293888).

Patient population

Patients with supratentorial gliomas who developed a significant post-operative

neurological deficit related to motor or language function were invited to take part in an off-label

treatment of FDA-approved rTMS. Subjects were only included in this study if TMS was

initiated within two weeks post-surgery. Assessments for motor dysfunction were made using the

standard Medical Research Council (MRC) 5-point scale [17]. To be eligible for rTMS therapy,

weakness in an arm or leg needed to be 4-/5 or worse in the hand, proximal arm, foot or proximal

leg at the time of treatment. Language dysfunction was defined using the Aphasia Rapid Test

(ART) with a score greater than 3 considered evidence of significant language disturbance [18].

Clinical assessment and Definition of Outcomes

Neurological assessments were performed immediately prior to treatment with rTMS and

one week following the last rTMS session by a blinded team member. Improvement in motor

function was defined as grade strength to at least 4+/5 in the affected limb, with either functional

hand control or the ability to walk with assistance in the leg. In cases of hemiplegia,

improvement in either hand or leg function was considered improvement. Finally, reduction in

the patient's pre-treatment ART score by 3 or more points was considered improvement in

language.

Connectome-based TMS target selection in neurosurgical patients

Once recruited, participants underwent a T1-weighted MPRAGE and resting-state fMRI

scan. The cortical target was selected based on the patient's primary deficit (i.e. motor or

language), our interpretation of any network fragmentation, and our experience with network

topology from normative connectomes (i.e. HCP data) [7,19,20].

Imaging Acquisition and Pre-processing Parameters

The resting-state fMRI was performed on a Phillips 3T Achieva which was acquired as a

T2-star EPI sequence, with $3 \times 3 \times 3$-mm voxels, 128 volumes/run, a TE = 27 ms, a TR = 2.8 s, a

field of view = 256 mm, a flip angle = 90˚ and an 8 minute total run time. Resting-state and

diffusion pre-processing was performed using in-house custom machine learning algorithms in

Python. Standard image processing steps included skull stripping, motion correction with a 6-

dimensional rigid body registration, correcting for physiological noise (CompCor), slice time

correction, spatial smoothing (6 FWHM Gaussian kernel), high-pass filtering, and co-registration

to the patient's structural space[1]. Of critical importance, we do not warp the brain into a standard

space like Montreal Neurological Institute (MNI) or Talairach space at any stage of the

processing. The patients then had a diffusion sequence acquired for subsequent connectivity

analyses from patient-specific multi-modal imaging data.

Machine-learning Aided Parcellation for Brain Tumours

A fundamental challenge for interventional neurorehabilitation post-craniotomy is to apply a parcellation scheme to highly-distorted anatomical brains. The Glasser HCP parcellation scheme is a state-of-the art multi-modal neurobiological division of the cerebral cortex [21]. However, it was not designed to be applied to brains with large lesions and oedema. We aimed to directly address this challenge by determining new HCP parcellation locations by using a proprietary machine learning algorithm (Omniscient Technologies) –Figure 1 is the connectome construction pipeline and Figure 2 represents sample outputs. Using a supervised machine learning approach, we first trained our algorithms to identify each HCP parcel using network connectivity from a normative dataset. Then, we applied our machine to identify the most appropriate HCP parcels in brains after supratentorial tumour surgery based on the same input imaging data. To our knowledge, this approach is unique in that previous studies have resolved this issue by applying the HCP parcellation derived from healthy brains without any adjustment to cortical topology.

Comparative Connectome Analyses

To gain additional insight into network connectivity, we processed n=300 HCP connectomes to serve as a reference of healthy canonical brain network organisation. Using this normative data, we qualitatively compared healthy networks to those observed in patients with lesions in particular areas. For example, we compared the normative visual areas to a patient with hemianopia (Figure 3a) or normative language network topology with that of a patient with aphasia (Figure 3b). This intra-network analysis enabled us to perform a hypothesis-driven neuro-navigated rTMS target selection.

rTMS treatment paradigm

The rTMS treatment was initiated within 1-2 weeks after standard awake glioma surgery. We utilized theta burst stimulation (TBS) protocols in all patients. Details of the TMS protocol and rationale available in the SI. We performed treatment five times per day over five consecutive days. In between TMS sessions, patients underwent rehabilitative therapy.

122 *Complications and Adverse Events*

123   All complications and side effects were noted after each rTMS session and one-week

124 post-treatment. Seizures were defined as any observable seizure or possible seizure-like activity

125 during the course of treatment. Neurological complications included any new or worsening of

126 neurological dysfunction measured by the ART and MRC Motor scale.

128 Results

Preliminary safety and recruitment data regarding rTMS treatment in neurosurgical patients.

We successfully recruited 31/34 (91%) patients within two-weeks after glioma surgery

and treated them with rTMS. The median participant age was 58 years with 20 females and 14

males. 30 patients had WHO grade II-IV gliomas, while four patients had low grade gliomas. Of

all the participants, n=23 began rTMS therapy within a week of surgery, and n=31 began within

2 weeks of surgery. The remaining 3 participants underwent treatment at 2 months, 4 months and

12 months and excluded in the recruitment rate citing logistic concerns. In total, 31 participants

completed all planned treatment sessions with one participant missing one rTMS session due to a

rehabilitation bed becoming available the day of their last scheduled treatment. No participant

stopped therapy due to treatment intolerance. In 21 participants with a motor deficit, rTMS was

applied to the sensorimotor network with an improvement noted in 19 patients after one-week

following the last TMS session. In 13 participants with a language deficit, rTMS was applied to

the frontoparietal network with an improvement in 12 patients after one-week of the final

stimulation session.

Safety and preliminary efficacy of rTMS in neurosurgical patients

No participants reported any general or partial seizures or seizure-like events during the

course of treatment and follow-up. Four patients reported transient headaches which resolved at

the end of each individual session. Light headedness (n=1) and nausea (n=1) was also reported

but resolved before the start of the next session. Transient tingling was reported at the site of

stimulation during stimulation onset, but also resolved immediately. These results are consistent

with well-documented side-effects during rTMS of non-craniotomy patients [13,16,22]. We noted

no worsening of neurological deficits and no other obvious side effects. The Supplemental

Digital Content is a video of a typical procedure; the participants consented to publication of

his/her image. Two brief clinical vignettes are presented below.

Clinical Vignettes

Case 1:

A woman (age 60-65) with a left parietal glioblastoma presented with preoperative

aphasia and near complete hemiplegia. Following resection, she developed complete expressive

aphasia and right hemiplegia. Connectome analyses revealed that her sensorimotor networks

were fragmented as two independent parcellations, likely due to the destruction of the callosal

fibers. Specifically, the injured side demonstrated satellite areas anterior to the dysfunctional

sensorimotor networks (Figure 4). Additionally, the left frontoparietal network revealed a clear

component of Broca's area, area 55b, and an SMA component. However, the temporal

component appeared to be less organized, appearing abnormal compared to normative data.

Thus, to potentially enhance functional recovery and address both delocalised networks, we

sought to select a stimulation target that would lead to enhanced network recruitment.

Beginning on post-operative day five, we performed five days of daily continuous TBS

(cTBS) to both the middle of the right sensorimotor network and the posterior frontal component

of the right frontoparietal network (both targets treated once per day). We then performed

intermittent TBS (iTBS) to the areas of scattered activation in the posterior left temporal lobe

and the areas near the abnormal sensorimotor regions. This treatment was well tolerated, and by

the end of the treatment, the patient was able to ambulate with a cane and speak in full sentences.

There were no serious complications, however, she had some persistent arm weakness.

Case 2:

A man (70-75 years of age) with a posterior left insular glioblastoma had moderate pre-

operative expressive aphasia that persisted post-surgery. Connectome analyses demonstrated

that his posterior temporal region was appropriately organized but did not co-activate within the

same network as Broca's area (Figure 5) [6]. Thus, we hypothesized that this was the result of

inactivation of the arcuate fasciculus fibers by the tumor or related to oedema. We also noted that

he was recruiting the right analog of Broca's area, as both regions were functionally co-activated.

As a result, we chose to perform accelerated (spaced-delivery of stimulation [23]) iTBS to the left

posterior temporal site to enhance the recruitment of additional connections for speech

improvement. This treatment began on post-operative day four. At the end day five of rTMS, his

speech markedly improved with no complications to report. Nevertheless, he persisted with

residual paraphasia after his therapy.

Discussion

In this study, we demonstrate the safety of rTMS post-craniotomy with the goal of

promoting functional recovery. Specifically, we demonstrate that no seizures were induced in 31

patients post-craniotomy and transient side effects were reported in 6 patients. This work

complements safety data from dozens of rTMS studies completed in non-craniotomy individuals

[24,25]. Despite the uncontrolled and open-label nature of the study, we cautiously interpret that

rTMS can potentially facilitate functional recovery post-craniotomy.

Similar results have been illustrated in acute and chronic stroke patients suggesting the

possible role of TMS as a therapeutic modality for a variety of clinical conditions to facilitate

motor and language improvement [14]. Given the widely demonstrated safety profile of TMS, it

would be a disservice not to further investigate the efficacy of technology to optimize post-

surgical clinical outcomes. To fully harness interventional neurorehabilitation's potential for

neuro-oncological care, additional research is required in two areas: target engagement and

simulation protocol. Here, we elucidate the role of individualized TMS in standard inpatient

rehabilitation and discuss implications for future study on rTMS to optimize clinical outcomes.

Importance of Target Engagement and Stimulation Protocol

There is a growing body of evidence suggesting that effective TMS targeting is critical

for success. For example, using image guidance to target rTMS improves efficacy [26].

Furthermore, targeting brain networks affected by disease-related processes is crucial for

functional improvement. Recently, Momi and colleagues delivered TMS pulses to two

frontoparietal nodes (prefrontal and parietal) to enhance fluid intelligence tasks [22] – adding

another research consideration on multi-nodal, rather than uni-nodal, stimulation. In addition, it

is likely that different patients with the same clinical deficit may need different target(s) [27].

Hence, there are many ways to interpret these observations, however, we advocate establishing

"the right target for the right patient" as being critical to successful interventional rehabilitation.

Similar to target engagement, *stimulation protocol* is another important variable to

consider. There are numerous different TMS protocols available for use. However, TBS

protocols are better suited for neurosurgical patients. First, the lower stimulus intensities used in

TBS likely have a lower seizure risk [28]. Second, TBS protocols achieve similar effects with

shorter treatment times (typically 8 minutes per session) compared to standard 30 minutes with

10 Hz TMS protocols. This enables the use of accelerated protocols (spaced-delivery of

stimulation sessions [23]) which are useful in treating patients in a subacute paradigm. Finally,

the stimulation effects of TBS is believed to last 45-60 mins which may fit better when

coordinating inter-session rehabilitation [29,30]. Our view is that while seizures are a concern,

given our clinical experience in managing this problem concomitant with the low occurrence rate

of this complication, there is now sufficient evidence to justify offering neurosurgical patients

rTMS.

Connectome-based Stimulation for Cognitive Rehabilitation

In this study, we primarily focused on ameliorating motor and language deficits post-

surgery in glioma patients. However, many patients experience cognitive deficits post-surgery

and there are no clear guidelines on how to help these patients. The multiple demand (MD)

system is a domain-general cognitive control network that acts as a skeleton for executing

cognitive tasks [3,7]. Systematically studying this system and the implications of its removal

during surgery would be useful for predicting post-operative cognitive trajectories [31]. More

broadly, despite motor or language deficits in our cohort, the qualitative fundamental motivation

to rehab greatly varied between our individuals [32]. An increasing line of evidence suggests that

increasing the motivation to expend cognitive effort, rather than enhancing cognitive networks

themselves, would be more effective in bolstering goal-directed behaviour [33]. Thus, if

frontostriatal circuitry can be mapped and effectively modulated post-craniotomy, this would be

a significant advancement and become important for other areas of neurosurgery, such as limbic

surgery [34].

Establishing a TMS Clinic for a Neurosurgical Practice

Establishing a TMS Clinic for a Neurosurgical Practice

While rTMS is a well-developed field with standard techniques, treating post-craniotomy

patients posed some unique challenges. First, the benefit of TMS early in the post-operative

period appears important [35]. Due to logistical issues, not all patients were able to return within

one week of surgery and returned within 14 days. However, there are important limits to early

TMS intervention in neurosurgical patients. Chiefly, given the small risk of inducing a seizure,

patients with significant swelling and/or midline shifts are not optimal candidates for rTMS.

Furthermore, patients with seizure history due to a tumour should be excluded from TMS until

more evidence of its safety in these circumstances are available. Despite these issues, we now

feel rTMS can be safely performed as part of standard inpatient rehabilitation.

rTMS Therapy for Stroke and Surgery

rTMS Therapy for Stroke and Surgery

The literature on the role of TMS in motor and language functional recovery is well-

established in stroke patients, providing most of our insight into the current benefits and

limitations of this therapeutic modality. Thus, certain themes from stroke neurology may

cautiously applied to neuro-oncological patients to guide therapeutic stimulation. For example,

cerebral inflammation and angiogenesis are two of multiple overlapping processes between

glioma surgery and cerebral ischemic stroke pathways [36]. A recent meta-analysis on 841

patients across 20 randomized controlled trials (RCTs) demonstrates that rTMS is beneficial to

the treatment of post-stroke hemiplegia, especially in: lower limb functioning, grip strength, and

attenuating stroke severity [15]. Interestingly, cortical reorganization can be observed between

primary motor and secondary motor cortices in stroke patients to facilitate improved motor

functioning, leading authors to suggest the need for future customized TMS applications based

on the newly activated cortical pathways in these stroke patients [37]. Similar cortical re-

organization has also been demonstrated to facilitate language functioning following ischemic

stroke [38]. Thus, following iatrogenic injury due to tumor resection, it is likely that similar

cortical pathways responsible for motor functioning and motor learning can also be strengthened

with rTMS given they too demonstrate plasticity following tumor growth [39,40].

rTMS likely provides additional benefits in many patients following tumor resection,

while being precluded from some stroke patients, due to certain temporal factors which are

known to affect plasticity. For instance, certain gliomas may cause slower changes in cerebral

connections and therefore affect connectome plasticity differently compared to acutely damaging

stroke lesions[39]. Unfortunately, acute brain damage due to stroke often causes more localized

neuronal cell death and subsequent unimodular cortical organization [8]. This type of damage

may demonstrate less capacity for cerebral reorganisation compared to slow growing tumors (ie,

low-grade gliomas, LGG), which disrupts greater amounts of cortex but provides more

opportunity for functional reorganization possibly due to less abrupt, initial neuronal death [8].

Thus, even more importantly in tumor patients, individualized connectomic approaches can be

implemented before rTMS to identify any on-going network reorganization occurring from the

lesion and ultimately facilitate motor and language preservation or compensation. This would

enable an updated understanding of network connectivity which can be applied to effectively

target and strengthen formerly silent polysynaptic cortical pathways following tumor resection

[14,40]. Indeed, our study shows that intra-network analyses can *safely* enable hypothesis-driven

neuro-navigated rTMS target selections.

While the applications of TMS between stroke and surgical patients have not been

compared, their respective methods may differ and therefore preclude certain benefits which

have been demonstrated specifically in ischemic stroke patients. Unfortunately, no studies were

able to be identified which looked at post-surgical rehabilitation utilizing individualized rTMS

treatment. Most surgical studies incorporating TMS have confined their uses to intra-operative

functional mapping (ie, language mapping) [41]. The only post-surgical application of rTMS

identified investigated its ability to reduce pain following gastric bypass surgery [42].

Nonetheless, in stroke patients, the effects produced by TMS correlates with the specific TMS

protocol applied [14]. Specifically, a TBS protocol of 50 Hz with 80% of active motor threshold

intensity is believed to modulate motor learning through effects similar long-term potentiation

(LTP) and long-term depression (LTD), and has been applied in numerous stroke trials [14,43]. Our

study utilized bursts of 3 pulses delivered with a repetition rate of 50 Hz at 80% of motor

threshold for 400 continuous (cTBS) or intermittent (iTBS) trains. Still, while our protocol is

similar to those described for ischemic stroke patients and we too observed improvements in

language and motor functioning, possible differences in neuroplasticity as identified by

neurocomputational models between glioma and stroke patients suggests that specific rTMS

protocols may produce different cortical changes and subsequent functional recovery based on

the type cortical injury.

Future Directions for Interventional Neurorehabilitation

With the rapid advancements made in imaging and stimulation technologies [32], the

future is bright to continuously evolve the concept of interventional neurorehabilitation for

neuro-oncology. Importantly, pre-operatively predicting which patients will require post-

operative interventional support or predicting which patients will best respond to and benefit

from rTMS as a therapeutic adjunct would be highly valuable. rTMS treatment causes changes in

electroencephalographic (EEG) assessed- functional connectivity (FC) that correlates well with

clinical outcomes in certain patients. Thus, EEG-FC measures can provide accurate, early,

biomarkers to guide personalized clinical decisions for long-term rTMS treatments or not,

possibly saving hospital costs while improving patient quality of life over time [44]. A machine

learning algorithm can accurately predict (83%) which patients with major depressive disorder

(MDD) will respond to long-term rTMS treatment in just the first rTMS session [45]. Similar

studies have not been extended into the perioperative setting, but numerous studies have

established the role of TMS and fMRI data as biomarkers to predict motor recovery following

stroke, warranting further investigation following neuro-oncological resection [46,47]. Lastly,

interventional neurorehabilitation can also be utilised in other patient populations following

stroke-induced pain or movement disorders [48-50]

With rising open science and international collaborative efforts, prospective registry-

based clinical studies could be employed to overcome heterogeneous glioma populations and

derive more practical outcomes.

Study Limitations

This study, however, is not without key limitations. First, the uncontrolled and early-

nature of our intervention raises the possibility whether these patients would have improved

without treatment. Now that we have established the TMS safety profile and recruitment rate for

this complex patient population, future trials should employ prospective, randomised, double-

blinded active- and sham-controlled TMS to determine the efficacy of improving recovery

trajectories. While glioma patients are highly heterogenous given different tumors, different

degrees of cortical reorganisation, and different resections completed, strict inclusion criteria and

multi-site collaborations can overcome such limitations. An alternative approach would be to

conduct large-scale international prospective registry-based studies. Finally, we did not acquire

long-term outcome data in these patients. Nevertheless, qualitatively, all patients reported they

would undergo TMS therapy again and found that it assisted with their rehabilitative efforts.

Despite these limitations, our primary aim was to establish the safety profile and recruitment rate

for TMS post-craniotomy.

Conclusion

In conclusion, we present a proof-of-concept of 'interventional neurorehabilitation' for

neuro-oncological clinicians to take charge in driving cortical reorganisation and functional

recovery. Specifically, we demonstrate the safety profile and recruitment rate for connectome-

based TMS acutely post-surgery for glioma patients. Given the clear enthusiasm from our

patients, we believe that TMS treatment is of low-risk, well-tolerated, and could be of immense

therapeutic benefit.

354
355
356

REFERENCES

Bullmore, E. & Sporns, O. Complex brain networks: graph theoretical analysis of structural and functional systems. *Nat Rev Neurosci* **10**, 186-198, doi:10.1038/nrn2575 (2009).

Sporns, O.   (The MIT Press, 2010).

Duncan, J. The multiple-demand (MD) system of the primate brain: mental programs for intelligent behaviour. *Trends Cogn Sci* **14**, 172-179, doi:10.1016/j.tics.2010.01.004 (2010).

van den Heuvel, M. P. & Sporns, O. A cross-disorder connectome landscape of brain dysconnectivity. *Nat Rev Neurosci* **20**, 435-446, doi:10.1038/s41583-019-0177-6 (2019).

Hart, M. G., Romero-Garcia, R., Price, S. J. & Suckling, J. Global Effects of Focal Brain Tumors on Functional Complexity and Network Robustness: A Prospective Cohort Study. *Neurosurgery* **84**, 1201-1213, doi:10.1093/neuros/nyy378 (2019).

Poologaindran, A., Suckling, J. & Sughrue, M. E. Letter: Elucidating the Principles of Brain Network Organization Through Neurosurgery. *Neurosurgery* **87**, E80-E81, doi:10.1093/neuros/nyaa094 (2020).

7　Poologaindran, A., Lowe, S. R. & Sughrue, M. E. The cortical organization of language:
distilling human connectome insights for supratentorial neurosurgery.
8　Keidel, J. L., Welbourne, S. R. & Lambon Ralph, M. A. Solving the paradox of the
equipotential and modular brain: A neurocomputational model of stroke vs. slow-
growing glioma. *Neuropsychologia* **48**, 1716-1724,
doi:https://doi.org/10.1016/j.neuropsychologia.2010.02.019 (2010).
9　Cui, Z. *et al.* Individual Variation in Functional Topography of Association Networks in
Youth. *Neuron* **106**, 340-353 e348, doi:10.1016/j.neuron.2020.01.029 (2020).
10　Finn, E. S. *et al.* Functional connectome fingerprinting: identifying individuals using
patterns of brain connectivity.
11　Beaty, R. E. *et al.* Robust prediction of individual creative ability from brain functional
connectivity. *Proc Natl Acad Sci U S A* **115**, 1087-1092, doi:10.1073/pnas.1713532115
(2018).
12　Grossman, N. *et al.* Noninvasive Deep Brain Stimulation via Temporally Interfering
Electric Fields. *Cell* **169**, 1029-1041 e1016, doi:10.1016/j.cell.2017.05.024 (2017).
13　Brunoni, A. R. *et al.* Repetitive Transcranial Magnetic Stimulation for the Acute
Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-
analysis. *JAMA Psychiatry* **74**, 143-152, doi:10.1001/jamapsychiatry.2016.3644 (2017).
14　Hoyer, E. H. & Celnik, P. A. Understanding and enhancing motor recovery after stroke
using transcranial magnetic stimulation. *Restor Neurol Neurosci* **29**, 395-409,
doi:10.3233/RNN-2011-0611 (2011).
15　He, Y., Li K Fau - Chen, Q., Chen Q Fau - Yin, J., Yin J Fau - Bai, D. & Bai, D.
Repetitive Transcranial Magnetic Stimulation on Motor Recovery for Patients With
Stroke: A PRISMA Compliant Systematic Review and Meta-analysis.
16　Lefaucheur, J. P. *et al.* Evidence-based guidelines on the therapeutic use of repetitive
transcranial magnetic stimulation (rTMS).
17　Brain, M. R. C. G. o. *Aids to the Examiantion of the Peripheral Nervous System*.
(Balliere Tindall, 1986).
18　Azuar, C. *et al.* The Aphasia Rapid Test: an NIHSS-like aphasia test. *J Neurol* **260**, 2110-
2117, doi:10.1007/s00415-013-6943-x (2013).
19　Romero-Garcia, R. *et al.* Practical Application of Networks in Neurosurgery: Combined
3-Dimensional Printing, Neuronavigation, and Preoperative Surgical Planning. *World*
Neurosurg **137**, e126-e137, doi:10.1016/j.wneu.2020.01.085 (2020).
20　Briggs, R. G. *et al.* A Connectomic Atlas of the Human Cerebrum-Chapter 18: The
Connectional Anatomy of Human Brain Networks. *Oper Neurosurg (Hagerstown)* **15**,
S470-S480, doi:10.1093/ons/opy272 (2018).
21　Glasser, M. F. *et al.* A multi-modal parcellation of human cerebral cortex. *Nature* **536**,
171-178, doi:10.1038/nature18933 (2016).
22　Momi, D. *et al.* Cognitive Enhancement via Network-Targeted Cortico-cortical
Associative Brain Stimulation. *Cereb Cortex* **30**, 1516-1527, doi:10.1093/cercor/bhz182
(2020).
23　Cole, E. J. *et al.* Stanford Accelerated Intelligent Neuromodulation Therapy for
Treatment-Resistant Depression. *Am J Psychiatry* **177**, 716-726,
doi:10.1176/appi.ajp.2019.19070720 (2020).
24　Di Iorio, R. & Rossini, P. M. in *Navigated Transcranial Magnetic Stimulation in*
Neurosurgery　(ed Sandro M. Krieg)　67-83 (Springer International Publishing, 2017).

419	25	Rossi, S., Hallett, M., Rossini, P. M. & Pascual-Leone, A. Safety, ethical considerations,
420		and application guidelines for the use of transcranial magnetic stimulation in clinical
421		practice and research.
422	26	Ahdab, R., Ayache, S. S., Brugieres, P., Goujon, C. & Lefaucheur, J. P. Comparison of
423		"standard" and "navigated" procedures of TMS coil positioning over motor, premotor and
424		prefrontal targets in patients with chronic pain and depression. *Neurophysiol Clin* **40**, 27-
425		36, doi:10.1016/j.neucli.2010.01.001 (2010).
426	27	Drysdale, A. T. *et al.* Erratum: Resting-state connectivity biomarkers define
427		neurophysiological subtypes of depression. *Nat Med* **23**, 264, doi:10.1038/nm0217-264d
428		(2017).
429	28	Oberman, L., Edwards, D., Eldaief, M. & Pascual-Leone, A. Safety of theta burst
430		transcranial magnetic stimulation: a systematic review of the literature. *J Clin*
431		*Neurophysiol* **28**, 67-74, doi:10.1097/WNP.0b013e318205135f (2011).
432	29	Wischnewski, M. & Schutter, D. J. Efficacy and Time Course of Theta Burst Stimulation
433		in Healthy Humans. *Brain Stimul* **8**, 685-692, doi:10.1016/j.brs.2015.03.004 (2015).
434	30	Wilson, M. T. *et al.* Biophysical modeling of neural plasticity induced by transcranial
435		magnetic stimulation. *Clin Neurophysiol* **129**, 1230-1241,
436		doi:10.1016/j.clinph.2018.03.018 (2018).
437	31	Briggs, R. G. *et al.* The Frontal Aslant Tract and Supplementary Motor Area Syndrome:
438		Moving towards a Connectomic Initiation Axis. *Cancers* **13**,
439		doi:10.3390/cancers13051116 (2021).
440	32	Satterthwaite, T. D., Xia, C. H. & Bassett, D. S. Personalized Neuroscience: Common
441		and Individual-Specific Features in Functional Brain Networks. *Neuron* **98**, 243-245,
442		doi:https://doi.org/10.1016/j.neuron.2018.04.007 (2018).
443	33	Westbrook, A. *et al.* Dopamine promotes cognitive effort by biasing the benefits versus
444		costs of cognitive work. *Science* **367**, 1362-1366, doi:10.1126/science.aaz5891 (2020).
445	34	Hurwitz, T. A., Honey, C. R., McLeod, K. R., Poologaindran, A. & Kuan, A. J.
446		Hypoactivity in the Paraterminal Gyrus Following Bilateral Anterior Capsulotomy. *Can J*
447		*Psychiatry* **65**, 46-55, doi:10.1177/0706743719874181 (2020).
448	35	Volz, L. J. *et al.* Shaping Early Reorganization of Neural Networks Promotes Motor
449		Function after Stroke. *Cereb Cortex* **26**, 2882-2894, doi:10.1093/cercor/bhw034 (2016).
450	36	Ghosh, M. K., Chakraborty, D., Sarkar, S., Bhowmik, A. & Basu, M. The
451		interrelationship between cerebral ischemic stroke and glioma: a comprehensive study of
452		recent reports. *Signal Transduction and Targeted Therapy* **4**, 42, doi:10.1038/s41392-
453		019-0075-4 (2019).
454	37	Sharma, N., Baron, J.-C. & Rowe, J. B. Motor imagery after stroke: relating outcome to
455		motor network connectivity. *Ann Neurol* **66**, 604-616, doi:10.1002/ana.21810 (2009).
456	38	Hamilton, R., Keenan Jp Fau - Catala, M., Catala M Fau - Pascual-Leone, A. & Pascual-
457		Leone, A. Alexia for Braille following bilateral occipital stroke in an early blind woman.
458	39	Kong, N. W., Gibb, W. R. & Tate, M. C. Neuroplasticity: Insights from Patients
459		Harboring Gliomas. *Neural Plast* **2016**, 2365063-2365063, doi:10.1155/2016/2365063
460		(2016).
461	40	Kawashima, A. *et al.* Plastic reshaping of cortical language areas evaluated by navigated
462		transcranial magnetic stimulation in a surgical case of glioblastoma multiforme.
463	41	Ille, S. *et al.* Resection of highly language-eloquent brain lesions based purely on rTMS
464		language mapping without awake surgery.

42   Borckardt Jj Fau - Reeves, S. T. *et al.* Fast left prefrontal rTMS reduces post-gastric
bypass surgery pain: findings from a large-scale, double-blind, sham-controlled clinical
trial.
43   Huang, Y. Z., Edwards Mj Fau - Rounis, E., Rounis E Fau - Bhatia, K. P., Bhatia Kp Fau
- Rothwell, J. C. & Rothwell, J. C. Theta burst stimulation of the human motor cortex.
44   Voigt, J., Carpenter, L. & Leuchter, A. Cost effectiveness analysis comparing repetitive
transcranial magnetic stimulation to antidepressant medications after a first treatment
failure for major depressive disorder in newly diagnosed patients - A lifetime analysis.
PLoS One **12**, e0186950-e0186950, doi:10.1371/journal.pone.0186950 (2017).
45   Corlier, J. *et al.* Changes in Functional Connectivity Predict Outcome of Repetitive
Transcranial Magnetic Stimulation Treatment of Major Depressive Disorder. *Cerebral*
cortex (New York, N.Y. : 1991) **29**, 4958-4967, doi:10.1093/cercor/bhz035 (2019).
46   Boyd, L. A. *et al.* Biomarkers of stroke recovery: Consensus-based core
recommendations from the Stroke Recovery and Rehabilitation Roundtable. *Int J Stroke*
12, 480-493, doi:10.1177/1747493017714176 (2017).
47   Kim, B. & Winstein, C. Can Neurological Biomarkers of Brain Impairment Be Used to
Predict Poststroke Motor Recovery? A Systematic Review.
48   Ren, H. *et al.* Application of Structural and Functional Connectome Mismatch for
Classification and Individualized Therapy in Alzheimer Disease. *Frontiers in Public*
Health **8**, 720 (2020).

49   Ivanishvili Z, Poologaindran A, Honey CR. Cyclization of motor cortex stimulation for
neuropathic pain: a prospective, randomized, blinded trial. Neuromodulation.
2017;20(5):497-503.

50 Slotty PJ, Poologaindran A, Honey CR. A prospective, randomized, blinded assessment of
multitarget thalamic and pallidal deep brain stimulation in a case of hemidystonia. Clin
Neurol Neurosurg. 2015;138:16-19.

491
492

Acknowledgements: AP is funded through a Turing Doctoral Scholarship from the Alan Turing

Institute and the National Science and Engineering Research Council of Canada. RRG is

supported by a *Guarantors of Brain* Fellowship.

Financial Disclosures: IMY is an employee of Cingulum Health. MES is the chief medical

officer of Omniscient and a shareholder of Cingulum Health. CT is a consultant for Aesculap.

All other authors report no conflict of interest related to this study.
500

501
502 **Author Contributions:** Conceptualization, AP, IMY and MES; Data curation, CP, IMY;

503 Formal analysis, AP, IMY.; Methodology, AP, RGB, MES; Project administration, IMY, CT.

504 and M.E.S.; Software SAA, KC, RRG; Writing—original draft, AP.; Writing—review and
505 editing, NBD, RRG, JS, MES.
506
507
508
509 **FIGURE LEGENDS**
510
Figure 1: The connectome construction pipeline used in this study. A) A standard Glasser atlas
was established using 300 healthy individuals from the Human Connectome Project (HCP). A
supervised machine learning algorithm was employed to recognise connectivity patterns for each
of the 360 HCP parcels in a healthy cohort. B) Using diffusion sequences, we applied
constrained spherical deconvolution (CSD) tractography to our patient cohort. Using these
images, our algorithm was applied to recognise and adjust the locations of HCP parcels in highly
atypical brains. C) After establishing maximal likely structural connectivity, we used this data to
inform and constrain functional connectivity using resting-state fMRI. D) Finally, structural and
functional anomaly matrices were generated to compare network connectivity differences (i.e.
language) between our patient and a normative atlas. Adopted with permission from Reference
[48].
522

523
524

Figure 2: Demonstration of proprietary machine learning algorithm (Omniscient) that assigns
parcellations to very distorted brains. Patient with a frontal lobe GBM and resected regions
resulting in total anterior brain shift. Figure 2a displays the modified location of the caudate
nucleus and the putamen. Figure 2b displays the modified location of the GP. Figure 2c displays
the modified location of the basal forebrain. Figure 2d displays the modified location of right 55b
parcellation. Figure 2e displays the modified location of the right PBelt. This allows for the
creation of a connectivity matrix of any brain despite .

534
535
536

Figure 3: 3a compares connectivity matrices of the left and right visual networks in a patient

with hemianopia. The left visual network is dotted mostly *blue*, which means that areas of the

visual system are not well synchronized to one another. By comparison, the right visual network

displays strong intra-network connectivity. Figure 3b compares the connectivity matrix of the

language area of a healthy control on the left with the language area connectivity of an aphasic

patient on the right. This aphasic matrix has the parcellations within the language system

anticorrelated, therefore, predominantly *blue*, suggestion loss of connectivity within the language

network. Note that columns 55b, 45 and STSdp are blue representing that they are isolated. We

hypothesized that this is in part due to problems with the superior longitudinal fasciculus/ arcuate

fasciculus system which links different components of the language system[7]. Conducting

connectomics analysis by comparing connectivity matrices enables us to generate potential

targets for TMS treatment.

Figure 4: TMS strategy for patient presenting with aphasia and near complete hemiplegia

secondary to glioblastoma. (a) Postoperative MRI of patient demonstrating resection cavity. (b)

Independent right sided (green) and left sided (orange) sensorimotor networks. Although

presented on the same image, these networks appeared as separate networks on connectomic

analysis. The anterior satellite areas in the left (orange) dysfunctional sensorimotor network. (c)

Left frontoparietal network demonstrating clear Broca's area and area 55b. The temporal

component of the network is disorganized. (d) cTBS was administered to both the middle of the

sensorimotor network and the right posterior frontal component of the right frontoparietal

network. (e) iTBS was administered to the disorganized temporal component of the left

frontoparietal network and the (f) anterior areas of the pathological left sensorimotor network.

Figure 5: TMS strategy for patient presenting with moderate expressive aphasia secondary to

glioblastoma. (a) Preoperative MRI (left) demonstrating left insula glioblastoma and

postoperative MRI (right) demonstrating complete resection. (b) Network analysis demonstrating

a strongly organized posterior temporal region that is not in in the same network as Broca's area.

This was the area that was selected for treatment with iTBS. (c). Further network analysis

demonstrating Broca's area with bilateral representation that is not in the same network as the

posterior temporal region.

578
579
580
581

582 **Supplemental Digital Content:** This video expands on the TMS technique described in the

583 Methods. The video illustrates patient set-up, patient registration, measuring motor threshold,

584 and TMS treatment. The participants consented to publication of his/her image.

585 https://www.dropbox.com/s/prp7dm3h7bsgm62/TMS_Demonstration_Video.mp4?dl=0

586
587

589
590
591
592